The threat of multi-drug resistance (MDR) among gram-negative and gram-positive pathogens has increased worldwide over recent years, impacting both hospital and community acquired infections. Bruker is addressing the need for rapid and accurate solutions to achieve fast identification and resistance detection from Positive Blood Cultures (PBC).
During the last decade, the MALDI Biotyper® has revolutionized the microbial identification, offering a fast, easy, robust, reliable and cost-effective solution. As part of this product evolution, Bruker has focused efforts on finding novel solutions using the MALDI Biotyper® to shorten microbial identification and phenotypic resistance detection of carbapenemase and cephalosporinase, within 60-90 minutes after PBC alert.
After subculturing of the PBC, confirmation of resistance mechanisms and quantification of microbial resistance by determination of true MICs is performed using the MICRONAUT broth microdilution (BMD) product portfolio. MICRONAUT provides accurate, complete and true MIC of microorganisms as well as detection of important resistance mechanisms of Ambler class A (ESBL, KPC), class B (MBL), class C (AMP-C) and class D (OXA-48-like) cephalosporinases and/or carbapenemases.
Bruker have taken further developments to support resistance management by offering a real-time PCR kit to detect presence of the big 5 carbapenemase genes from a rectal swab, for patients who are at risk of colonization from Carbapenamase Producing Enterobacteriaceae (CPE).